Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2018

View Archived Issues

Adipose-derived regenerative cell therapy safe in patients with erectile dysfunction

Polymorphisms in miRNA-146a and IRAK1 are associated with susceptibility to SLE and MS

Harbour BioMed licenses ex-China rights to Kelun-Biotech's A-167

Common pathway may underlie schizophrenia and PD

Getting at stored mRNAs part of fragile X problem

HDAC inhibitors optimized for CNS drug-like properties and hematological safety

Phase Ib data guide Novan's development of SB-414 for atopic dermatitis

New oral selective apelin agonist AM-2995 developed for heart disease treatment

Chugai's describes candidate for the treatment of hyperphosphatemia EOS-798

Novo Nordisk reports topline PIONEER 5 results for oral semaglutide

Phase III study of MC2-01 cream in psoriasis vulgaris meets primary and secondary endpoints

Biogen identifies new NRF2 activators

Adare Pharmaceuticals describes cysteamine prodrugs

Antiangiogenic compounds synthesized at Celgene

Vectura completes pediatric studies with VR-647 for asthma

Hanmi Science patents oncolytic compounds

New Rho kinase inhibitors described by Chiesi Farmaceutici

Japanese approval for Tagrisso as first-line treatment of EGFR-mutated NSCLC

Phase II trial of TLC-599 for osteoarthritis pain meets primary and key secondary endpoints

FDA approves expanded label for Keytruda for first-line treatment of metastatic non-squamous NSCLC

Ascentage Pharma opens phase I trial of APG-2575 in hematologic malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.